Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037544 | 1.00 | MAPT (0.55) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL9063455 | 0.86 | MAPT (0.50) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL3426260 | 0.84 | ACACB (0.64) | MAPTALDH1A1HTTHPGDLMNA | |
| SCHEMBL11749030 | 0.84 | MAPT (0.49) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL5044206 | 0.84 | MAPT (0.49) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL27773043 | 0.83 | HSD17B10 (0.53) | MAPTALDH1A1KDM4EHSD17B10HTT | |
| SCHEMBL27676416 | 0.82 | HTT (0.44) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL27676419 | 0.82 | HTT (0.44) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| Zinc Ion SCHEMBL2921239 | 0.81 | MAPT (0.47) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL28527565 | 0.81 | HSD17B10 (0.52) | MAPTHDAC6ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105797771-B | (R) Mn-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications | 上海应用技术学院 | 2018-05-15 | — | — | CN | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MAPT 680/4885HDAC3 1287/4885HDAC4 1085/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MAPT 517/4885HDAC3 2899/4885HDAC4 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.